Sleep Disorders Trial, Recruiting NCT05649514 Sponsor: University Hospital, Montpellier Condition: Sleep Disorders
Back to Sleep Disorders

Sleep Disorders Trial, Recruiting

NCT05649514
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with mild Alzheimer's disease, with a memory test score between 21 and 30 out of 30
  • You are either not taking Alzheimer's medications (such as donepezil or memantine), or you have been on a stable dose of these medications for at least 3 months
  • You are either not taking antidepressants or anxiety medications, or you stopped taking them at least 15 days ago
  • You have a family member or carer who is able to fill in questionnaires, rating scales, and sleep diaries as part of the study
  • You are willing and able to sign a consent form agreeing to take part
  • You are able to attend all study visits and follow the study procedures
  • You are registered with the French social security system

Who may not be able to join:

  • You have a genetic (inherited) form of Alzheimer's disease
  • There is not enough medical information available to confirm your Alzheimer's diagnosis
  • You currently live in a care home or nursing home
  • You are unable to read or are unable to complete psychological and behavioural tests
  • You have significant physical or sensory problems (such as serious hearing or vision difficulties) that could interfere with the tests
  • You are currently under a court or government restriction on your freedom
  • You have been diagnosed with severe depression according to recognised medical guidelines (DSM-5)
  • You are considered a protected adult under French law (confirm with trial site)
  • You have a serious medical condition that is considered life-threatening in the short term

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Karim BENNYS, MD, University Hospital, Montpellier

Phone: +33467335219

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 February 2025
Est. completion
1 August 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Change in the Alzheimer's Disease Cooperative Study - Preclinical Alzheimer Cognitive (ADCS-PACC) scale score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov